Neurocrine Biosciences, Inc.
561 articles about Neurocrine Biosciences, Inc.
-
Neurocrine's NBI-827104 failed to meet the primary endpoint in a Phase II study for epileptic encephalopathy with continuous spike-and-wave during sleep, the company announced Tuesday.
-
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep
12/6/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that investigational NBI-827104 did not meet its primary endpoint in the Phase 2 STEAMBOAT™ study evaluating the efficacy, safety, tolerability and pharmacokinetics of NBI-827104 compared to placebo in pediatric patients with epileptic encephalopathy with continuous spike-and-wave during sleep (EE-CSWS).
-
Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022
12/2/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today reported demographic and clinical characteristics data from genetic screening-based studies of children with SCN8A -related epilepsies.
-
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences - November 08, 2022
11/8/2022
Neurocrine Biosciences, Inc. announced that members of the management team will participate at the following investor conferences.
-
Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022
11/3/2022
Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a leading neuroscience-focused biopharmaceutical company, today reported additional results from the Phase 3 KINECT-HD study investigating valbenazine for the treatment of chorea associated with Huntington Disease (HD).
-
Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsules at the American Society of Consultant Pharmacists (ASCP) 2022 Annual Meeting
11/3/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data from a study on INGREZZA® (valbenazine) capsules evaluating in vitro dissolution performance of whole intact or crushed capsule contents in 40 mg and 80 mg strength.
-
Neurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance
11/1/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2022 and raised net sales guidance for INGREZZA in 2022.
-
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia
10/27/2022
Neurocrine Biosciences, Inc. today announced the first patient has been randomized for its Phase 2 placebo-controlled, inpatient clinical study evaluating the efficacy, safety, tolerability, and pharmacokinetics of investigational compound NBI-1117568 in adults with schizophrenia.
-
Neurocrine Biosciences Presents Real-World Parkinson's Disease Patient Characteristics From ONGENTYS® (opicapone) Open-Label Study at ANA2022
10/24/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented data detailing the baseline characteristics of patients with Parkinson's disease (PD) in the Opicapone Treatment Initiation Open-Label Study (OPTI-ON).
-
Neurocrine Biosciences Presents Data on Benztropine Use Among People Treated with Antipsychotics at the 2022 American Psychiatric Nurses Association (APNA) Annual Conference
10/19/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced data on the real-world comorbidities, polypharmacy, and treatment patterns of patients on newly prescribed benztropine who were also being treated with antipsychotic medications.
-
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2022 Financial Results
10/11/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2022 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on November 1, 2022.
-
Neurocrine Biosciences Appoints Dr. Ingrid Delaet as Chief Regulatory Officer
9/29/2022
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that Dr. Ingrid Delaet will join the company's executive management team as Chief Regulatory Officer effective October 1, leading the regulatory affairs, quality assurance, medical writing, and program management teams. Dr. Delaet has served as Vice President of Regulatory Affairs at Neurocrine since January 2021.
-
Neurocrine Biosciences Presents INGREZZA® (valbenazine) Data on Sustained Treatment Response at Psych Congress 2022
9/19/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data demonstrating sustained improvements with long-term INGREZZA ® (valbenazine) capsules treatment in adults with tardive dyskinesia (TD) at the Psych Congress 2022 scientific meeting being held September 17-20.
-
Neurocrine Biosciences to Present Study Findings on Evolving Tardive Dyskinesia Education Needs of Physicians at the 2022 MDS International Congress
9/15/2022
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the presentation of survey findings demonstrating the need for education on supportive evidence regarding best approaches to managing tardive dyskinesia (TD) symptoms while maintaining control of the underlying psychiatric disorder.
-
Neurocrine Biosciences Presents New Post-Hoc Analysis of ONGENTYS® (opicapone) Capsules Effect on COMT Activity at the 2022 MDS International Congress
9/15/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today will present data on the effects of ONGENTYS® (opicapone) capsules on soluble-catechol-O-methyltransferase (S-COMT) enzyme inhibition.
-
Parkinson & Movement Disorder (PMD) Alliance and Neurocrine Biosciences Announce New Survey Results Revealing the Significant Impact OFF Time Has on People with Parkinson's Disease and Their Care Partners
9/12/2022
Parkinson & Movement Disorder Alliance, in partnership with Neurocrine Biosciences, a leading neuroscience-focused biopharmaceutical company committed to meeting the needs of people with complex and debilitating disorders, announced results from the Survey Assessment: Impact of OFF Time on People with Parkinson's Disease and Their Care Partners.
-
Neurocrine Biosciences to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
9/6/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 20th Annual Global Healthcare Conference at 10:35 a.m. Eastern Time on Tuesday, September 13, 2022 in New York. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference.
-
Mesoblast fell short of analyst forecasts this week, and money is pouring into glaucoma, medical devices for heart disease and chronic endocrine conditions.
-
This week, drugs developed by Neurocrine Biosciences, Akebia, Eliem and Athira all failed to meet expectations in clinical trials.
-
Neuro News: Acadia Receives CRL, Sosei and Microglia Advance Schizophrenia Treatment & More
8/5/2022
This week's highlights in neurological diseases include Acadia receiving a CRL for its ADP drug, Sosei and Neurocrine's schizophrenia drug study moving on to Phase II.